Your session is about to expire
← Back to Search
Cortisol Synthesis Inhibitor and Benzodiazepine
EMB-01 for Tobacco Use Disorder
Phase 2 & 3
Waitlist Available
Research Sponsored by Rose Research Center, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Has signed the ICF and is able to read and understand the information provided in the ICF.
Healthy smokers 21 to 65 years of age (inclusive) at screening.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights
Study Summary
This study is evaluating whether a drug combination may help smokers quit.
Eligible Conditions
- Tobacco Use Disorder
- Smoking Cessation
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Smoking Abstinence
Trial Design
1Treatment groups
Experimental Treatment
Group I: EMB-001Experimental Treatment1 Intervention
EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).
Find a Location
Who is running the clinical trial?
Rose Research Center, LLCLead Sponsor
15 Previous Clinical Trials
1,432 Total Patients Enrolled
5 Trials studying Tobacco Use Disorder
270 Patients Enrolled for Tobacco Use Disorder
Foundation for a Smoke Free World INCOTHER
14 Previous Clinical Trials
2,124 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
66 Patients Enrolled for Tobacco Use Disorder
Embera NeuroTherapeutics, Inc.Industry Sponsor
6 Previous Clinical Trials
194 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
40 Patients Enrolled for Tobacco Use Disorder
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger